ABBVIE INC. vs. SELLAS Life Sciences Group, Inc. Common Stock
SELLAS Life Sciences Group, Inc. Common Stock (SLS) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| ABBV | SLS | |
|---|---|---|
| Market Cap | $468.22 billion | $3.12 billion |
| Revenue (TTM) | $64.39 billion | — |
| Net Income (TTM) | $6.32 billion | — |
ABBV leads on 1 of 1 size & scale factors.
Valuation
| ABBV | SLS | |
|---|---|---|
| P/E Ratio | 74.85 | — |
| Price / Book | -79.52 | — |
| Price / Sales | 7.27 | — |
ABBV and SLS split the valuation factors evenly.
Profitability
| ABBV | SLS | |
|---|---|---|
| Net Margin | 9.81% | — |
| Return on Equity | -107.29% | — |
ABBV and SLS split the profitability factors evenly.
Dividend
| ABBV | SLS | |
|---|---|---|
| Dividend Yield | 2.61% | 6.22% |
| Payout Ratio | 195.48 | — |
SLS leads on 1 of 1 dividend factors.
Risk & Sentiment
| ABBV | SLS | |
|---|---|---|
| Short Interest | 0.85% | 0.06% |
SLS leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, SLS overview, SLS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.